Acute myeloid leukemia trials in Finland

In Finland 12 Also abroad 761

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Helsinki, Kuopio, Oulu, Tampere, Turku
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 3Taking people
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Where
Helsinki, Tampere
Age
18 years to 75 years
People
650 worldwide
Run by
University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Helsinki, Tampere
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Where
Helsinki, Kuopio, Oulu, Tampere, Turku
Age
Up to 64 years
People
675 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Helsinki, Oulu, Tampere, Turku
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 1/2Not yet taking people in Finland
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Helsinki, Turku
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Helsinki, Tampere
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
Phase 2Taking people
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Where
Helsinki, Kuopio, Oulu, Tampere, Turku
Age
1 month to 18 years
People
60 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01
Phase 3Taking people
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Where
Helsinki
Age
Up to 18 years
People
170 worldwide
Run by
Vastra Gotaland Region
See details and how to joinNCT05477589
No phaseEnrolling by invitation
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Where
Turku
Age
18 years to 100 years
People
30
Run by
Turku University Hospital
See details and how to joinNCT05212103
Phase 3Taking people
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Where
Helsinki, Kuopio, Oulu, Tampere, Turku
Age
Up to 64 years
People
730 worldwide
Run by
Vaestra Goetalandsregionen
See details and how to joinNCT01828489 · EU 2024-518254-16-00
Phase 2Taking people
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Where
Helsinki, Kuopio, Oulu, Tampere
Age
18 years and over
People
117 worldwide
Run by
Copenhagen University Hospital, Rigshospitalet
See details and how to joinNCT05431257 · EU 2023-510415-19-00